Cindy Leissinger
Hematology & Oncology · New Orleans, LANPI 1700839933
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $95,504 of the $134,905 with a category attached, or 70.8%. It is spread thinly across 27 manufacturers, the largest accounting for just 20.4%. Reporting peaked in 2019 at $43,141 and has fallen 98.4% since, to $683 in 2025. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $956.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$28K
- Takeda Pharmaceuticals U.S.A., Inc.$27K
- Shire North American Group Inc$24K
- Bayer$13K
- Global Blood Therapeutics, Inc.$10K
- Pfizer$9K
- plus $25K from 21 others
Across 42 payments — averaging $7080.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$137K
- Octapharma USA, Inc.$43K
- Sanofi US Services Inc.$39K
- Bio Products Laboratory USA, Inc.$33K
- Genentech, Inc.$30K
- Novo Nordisk AS$7K
- plus $9K from 3 others
What the payments were for
- Consulting fees$95,50471%
- Speaking & faculty fees$31,46523%
- Travel & lodging$4,7274%
- Food & beverage$3,2082%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 27 | $27,559 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $26,869 |
| Shire North American Group Inc | 28 | $23,568 |
| Bayer | 18 | $12,914 |
| Global Blood Therapeutics, Inc. | 3 | $10,414 |
| Pfizer | 15 | $8,604 |
| Dova Pharmaceuticals | 5 | $6,016 |
| Genentech USA, Inc. | 3 | $4,751 |
| Bioverativ Therapeutics Inc. | 1 | $3,842 |
| Biomarin Pharmaceutical Inc. | 6 | $3,237 |
| Kedrion Biopharma Inc. | 1 | $2,600 |
| Chiesi USA, Inc. | 1 | $2,100 |
| Sanofi | 2 | $1,856 |
| EMD Serono, Inc. | 1 | $111 |
| Novartis | 4 | $84 |
| Merck | 4 | $74 |
| Novo Nordisk | 1 | $69 |
| Astellas Pharma US Inc | 2 | $47 |
| HEMA Biologics, LLC | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $28 |
| AbbVie | 1 | $23 |
| AstraZeneca | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$134,905 in reported general payments places this provider in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 24 | $5,053 |
| Tranexamic Acid | 18 | $1,626 |
| Fondaparinux Sodium | 14 | $1,399 |
| Hydroxyurea | 22 | $363 |
| Warfarin Sodium | 48 | $294 |
| Deferasirox | 11 | $240 |
| Celecoxib | 14 | $145 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New Orleans
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Marc MatranaNew Orleans$757K
- Lingling duNew Orleans$173K
- Carter DavisNew Orleans$61K
- Furhan YunusNew Orleans$55K
- Michelle LochNew Orleans$50K
- David MorrisonNew Orleans$23K
- Scott SonnierNew Orleans$20K
- Ralph MillettNew Orleans$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.